NCT07215520View on ClinicalTrials.gov

Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

October 20, 2025

Primary Completion Date

August 19, 2026

Study Completion Date

August 19, 2026

Conditions
COVID-19
Interventions
BIOLOGICAL

NDV-HXP-S-KP.2

Nasal Administration of a COVID-19 vaccine to compare against a commercially available mRNA vaccine

BIOLOGICAL

COVID-19 mRNA Vaccine

Used as a comparator to study vaccine

Trial Locations (1)

80917

Skylight Health Research, Colorado Springs

All Listed Sponsors
lead

CastleVax Inc.

INDUSTRY